Pantesin, an Active Derivative of Vitamin B5, Used as a Nutritional Supplement, Significantly Lowers Cardiovascular (CV) Disease Markers in Low to Intermediate CV Risk North American Subjects: A Triple‐Blind Placebo/Diet Controlled Study
John A. Rumberger, Malkanthi Evans, Joseph Napolitano, Isao Azumano, Toshikazu Kamiya · The FASEB Journal · 2010
Serum cholesterol (C), LDL‐C, non‐HDL‐C, and apolipoprotein B (apo‐B) are well established risk markers for CV disease. The effect (and safety) of Pantesin (Daiichi Fine Chemicals) versus placebo on these risk markers was studied in 120 subjects (n=60/group) who were low to intermediate CV disease risk (NCEP ATP III) at screening. All subjects completed a 4 week diet lead‐in (TLC – Therapeutic Lifestyle Change) prior to randomization (baseline). Results for LDL‐C: LDL‐C (mg/dL) Screening Baseline 4‐weeks 8‐weeks 16‐weeks Placebo 115±26 108±25 112±28 114±29 115±27 Pantesin 112±24 (NS) 112±31 (NS) 104±27 104±28 108±30 = p≤0.005 NS = non‐significant; data are mean±SD Conclusion Pantesin supplementation for 16 weeks (600 mg/d for 8 weeks then 900 mg/d for 8 weeks) significantly lowered LDL‐C as well as apo‐B (p=0.010) and non‐HDL‐C (p<0.001) over and above the effect of TLC diet alone. Pantesin was well tolerated with no differences between groups in adverse events. These results are noteworthy as prior studies have shown each 1 mg/dL reduction in LDL‐C lowers CV risk by 1%.